Centre for Inherited Heart Disease, Department of Cardiology, Kauvery Hospital, Chennai, India.
Principal Scientist, Operations, Medgenome Labs, Bengaluru, India.
Indian Heart J. 2024 Jul-Aug;76(4):260-267. doi: 10.1016/j.ihj.2024.07.002. Epub 2024 Jul 14.
This study aims to analyze the results of comprehensive genetic testing in patients presenting to a dedicated multidisciplinary inherited heart disease clinic in India.
All patients presenting to our clinic from August 2017 to October 2023 with a suspected inherited heart disease and consenting for genetic testing were included. The probands were grouped into familial cardiomyopathies namely hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), arrhythmogenic cardiomyopathy (ACM) and peripartum cardiomyopathy (PPCM), channelopathies namely congenital long QT syndrome (LQTS) and Brugada syndrome (BrS), and heritable connective tissue disorder namely Marfan Syndrome (MFS). Next generation sequencing (NGS) was used, and pre-test and post-test counseling were provided to probands and cascade screening offered to relatives.
Mean age of the subjects (n = 77; 48 probands, 29 relatives) was 43 ± 18 years, 68 % male and 44 % symptomatic, with 36 HCM, 3 DCM, 3 ACM, 1 PPCM, 3 LQTS, 1 BrS and 1 MFS probands. The diagnostic yield of NGS-based genetic testing was 31 %; variants of uncertain significance (VUS) were identified in 54 %; and 15 % were genotype-negative. Twenty-nine relatives from 18 families with HCM (n = 12), DCM (n = 3), ACM (n = 2) and MFS (n = 1) underwent genetic testing. The genotype positive probands/relatives and VUS carriers with strong disease phenotype and/or high risk variant were advised periodic follow-up; the remaining probands/relatives were discharged from further clinical surveillance.
Genetic testing guides treatment and follow-up of patients with inherited heart diseases and should be carried out in dedicated multidisciplinary clinics with expertise for counseling and cascade screening of family members.
本研究旨在分析在印度一家专门的多学科遗传性心脏病诊所就诊的患者进行综合基因检测的结果。
纳入 2017 年 8 月至 2023 年 10 月间因疑似遗传性心脏病就诊并同意进行基因检测的所有患者。将先证者分为家族性心肌病,即肥厚型心肌病(HCM)、扩张型心肌病(DCM)、致心律失常性心肌病(ACM)和围产期心肌病(PPCM)、通道病,即先天性长 QT 综合征(LQTS)和 Brugada 综合征(BrS)以及遗传性结缔组织疾病,即马凡综合征(MFS)。使用下一代测序(NGS),并在先证者中提供检测前和检测后咨询,为亲属提供级联筛查。
共纳入 77 名患者(48 名先证者,29 名亲属),平均年龄为 43 ± 18 岁,68%为男性,44%有症状,其中 36 例为 HCM、3 例为 DCM、3 例为 ACM、1 例为 PPCM、3 例为 LQTS、1 例为 BrS 和 1 例为 MFS 先证者。基于 NGS 的基因检测诊断率为 31%;发现 54%的变异意义不确定(VUS);15%为基因阴性。18 个 HCM(n=12)、DCM(n=3)、ACM(n=2)和 MFS(n=1)家族中有 29 名亲属接受了基因检测。基因型阳性的先证者/亲属和 VUS 携带者,如具有强烈疾病表型和/或高风险变异的携带者,建议定期随访;其余的先证者/亲属则停止进一步的临床监测。
基因检测指导遗传性心脏病患者的治疗和随访,应在具有专业咨询和家族级联筛查知识的专门多学科诊所中进行。